What is Flyte?
Flyte, developed by Pelvital USA, represents a significant advancement in the treatment of stress urinary incontinence. The company provides an FDA-cleared, intravaginal device that utilizes mechanotherapy to facilitate cellular healing and restore bladder control. By integrating a digital health application with a hardware-based therapeutic solution, Flyte offers a comprehensive, home-based alternative to traditional surgical procedures. This dual-pronged approach—combining clinical-grade medical devices with patient-centric digital support—positions the company at the intersection of FemTech and connected health, addressing a massive, underserved demographic with evidence-based, non-invasive solutions.
How much funding has Flyte raised?
Flyte has raised a total of $5M across 1 funding round:
Angel/Seed
$5M
Angel/Seed (2024): $5M with participation from Wisconsin Investment Partners, Pier 70 Ventures, VisionTech Partners, Life Science Angels, Boomerang Ventures, and Blue Pacific Fund
Key Investors in Flyte
Pier 70 Ventures
A venture firm dedicated to impact-driven healthcare technologies, providing capital and mentorship to accelerate high-growth, sustainable medical innovations.
Boomerang Ventures
A specialized venture studio and fund focused on connected health technologies, assisting startups in navigating the complex path from ideation to market commercialization.
Life Science Angels
A premier angel investment group with a deep focus on early-stage life science companies, providing critical support to entrepreneurs in the medical and biotech sectors.
What's next for Flyte?
With this major enterprise-level funding, Flyte is poised to scale its operations and deepen its market penetration. The strategic roadmap likely involves expanding its clinical validation studies, enhancing the digital user experience through its proprietary app, and scaling its distribution channels to reach a broader patient base. As the company transitions from its early-stage development phase into a period of rapid commercial growth, the focus will remain on de-risking the adoption of its medical device while maintaining the high standards of clinical efficacy that have defined its initial success. The capital will serve as a catalyst for operational excellence and long-term value creation in the competitive healthcare technology market.
See full Flyte company page
